Supplements

Supplements refer to concentrated nutritional or botanical compounds taken orally to address specific physiological indications. Unlike pharmaceuticals, they face minimal pre-market regulation in most jurisdictions, which creates substantial variability in product quality, bioavailability, and label accuracy. Third-party verification (USP, NSF International, ConsumerLab) addresses identity, potency, and contaminant screening but does not verify clinical efficacy.

Evidence-based supplementation follows a diagnostic principle: identify and correct measured deficiency rather than supplementing broadly against assumed deficit. Biomarker-driven protocols (ferritin for iron, 25-hydroxyvitamin D for vitamin D, RBC magnesium, homocysteine for B vitamins) identify actionable interventions with predictable benefit. In contrast, shotgun supplementation obscures attribution, increases interaction risk, and typically produces null clinical change despite subjective expectation.

Bioavailability varies substantially by form. Iron bisglycinate outperforms ferrous sulfate on tolerability at equivalent absorption. Magnesium glycinate and L-threonate serve different indications than citrate or oxide. Vitamin D3 (cholecalciferol) is preferred over D2 (ergocalciferol). Methylfolate bypasses MTHFR polymorphisms that reduce conversion from synthetic folic acid. Product selection should match both the indication and individual biochemistry where known. Reassessment at 8-12 weeks with repeat biomarkers determines whether intervention should continue, adjust, or discontinue.